In contrast, subjects with a PD-L1-negative disease (CPS = 0), accounting for 15% of the R/M HNSCC patient population [2], are treated with platinum-based chemotherapy plus cetuximab. Here, CD274 is linked to head and neck squamous cell carcinoma.